Chiome Bioscience (TSE:4583) EPS (Basic): 円-7.34 (TTM As of Dec. 2025)


TSE:4583 Chiome Bioscience Inc TSE:4583
50 GF Score
Price 円66.00
GF Value 円82.68
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience EPS (Basic)?

Chiome Bioscience TSE:4583 50 EPS (Basic) is 円-7.34 as of Dec. 2025. GuruFocus rates TSE:4583 with a GF Score™ of 50/100 and a GF Value™ of 円82.68 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Chiome Bioscience's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was 円0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-7.34.

Chiome Bioscience's EPS (Diluted) for the three months ended in Dec. 2025 was 円0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-7.34.

Chiome Bioscience's EPS without NRI for the three months ended in Dec. 2025 was 円0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -7.34.

During the past 3 years, the average EPS without NRI Growth Rate was 19.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Chiome Bioscience's highest 3-Year average EPS without NRI Growth Rate was 20.10% per year. The lowest was -135.80% per year. And the median was 3.55% per year.

Chiome Bioscience  (TSE:4583) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Chiome Bioscience EPS (Basic) Related Terms

Chiome Bioscience EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience EPS (Basic) Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.74 -28.26 -24.62 -17.54 -14.47

Chiome Bioscience Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -3.94 -4.03 0.00 -3.31
TSE:4583
50GF Score
Chiome Bioscience Inc TSE:4583
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Chiome Bioscience's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-982.779-0)/67.912
=-14.47

Chiome Bioscience's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0-0)/67.912
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-7.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円-7.34 mean?
Chiome Bioscience (TSE:4583) has a EPS (Basic) of 円-7.34 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chiome Bioscience and its competitors.
Is Chiome Bioscience's EPS (Basic) too high?
Chiome Bioscience's current EPS (Basic) is 円-7.34. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's EPS (Basic) compare to VRTX and REGN?
Chiome Bioscience's EPS (Basic) of 円-7.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current EPS (Basic) is 円-7.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Undervalued. The stock's GF Value™ is 円82.68, compared to a current price of 円66.00 — trading 20.2% below its estimated fair value. The current EPS (Basic) is 円-7.34. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current EPS (Basic) is 円-7.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円66.00 is trading 20.2% below its estimated GF Value™ of 円82.68. GuruFocus considers Chiome Bioscience to be Modestly Undervalued.

Key valuation signals for TSE:4583:

  • EPS (Basic): 円-7.34
  • GF Value™: 円82.68 vs. price of 円66.00 (20.2% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score

Get the complete analysis for TSE:4583

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円66.00
Price
円82.68
GF Value